PUBLISHER: Inkwood Research | PRODUCT CODE: 1516692
PUBLISHER: Inkwood Research | PRODUCT CODE: 1516692
Japan Cancer Pain Management Market Forecast 2024-2032
KEY FINDINGS
The Japan cancer pain management market is expected to grow with a CAGR of 5.75% during the forecast period 2024-2032.
MARKET INSIGHTS
According to the National Institutes of Health study, Cancer Prevalence Projections in Japan and Decomposition Analysis of Changes in Cancer Burden, 2020-2050, cancer prevalence in Japan is expected to rise significantly by 2050. The total number of cancer cases is projected to reach 3,665,900, with a possible range from 3,210,200 to 4,201,400 cases, marking a 13.1% increase from 2020. A notable aspect of this increase is the gender disparity. Female cancer survivors are projected to increase by 27.6%, while male survivors will see a modest rise of only 0.8%. Consequently, from 2040 onward, the number of female cancer survivors will surpass that of males.
By 2050, colorectal, female breast, prostate, lung, and stomach cancers are anticipated to be the most prevalent cancer types, comprising 66.4% of all cancer survivors in Japan. For males, the cancers with the highest projected absolute increases in prevalence include prostate, lung, and malignant lymphoma. In contrast, for females, the most significant increases are expected in breast, colorectal, and corpus uteri cancers. This growing cancer prevalence underscores the need for effective cancer pain management solutions.
Japan has made significant strides in managing cancer-related pain, recognizing it as an essential part of comprehensive cancer care. To enhance cancer pain treatment for patients, the country has adopted various strategies, such as setting up palliative care units and incorporating pain management protocols within oncology departments.
Moving ahead, opioid analgesics are commonly used to manage moderate to severe cancer pain. Japan follows international guidelines for opioid use, ensuring that patients receive adequate pain relief while minimizing the risks of addiction and side effects. These guidelines for cancer pain medications are part of a broader strategy to manage pain effectively. Additionally, the Japanese healthcare system promotes multidisciplinary approaches involving oncologists, palliative care specialists, nurses, and pharmacists to provide holistic pain management.
SEGMENTATION ANALYSIS
The report on the Japan cancer pain management market includes the segmentation analysis based on drug type and disease indication.
Market by Drug Type:
- Opioids
- Morphine
- Fentanyl
TABLE OF CONTENTS
1. RESEARCH SCOPE & METHODOLOGY
- 1.1. STUDY OBJECTIVES
- 1.2. METHODOLOGY
- 1.3. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
- 2.1. MARKET SIZE & ESTIMATES
- 2.2. COUNTRY SNAPSHOT - JAPAN
- 2.3. COUNTRY ANALYSIS - JAPAN
- 2.4. SCOPE OF STUDY
- 2.5. CRISIS SCENARIO ANALYSIS
3. MARKET DYNAMICS
4. KEY ANALYTICS
5. MARKET BY DRUG TYPE
6. MARKET BY DISEASE INDICATION
7. COMPETITIVE LANDSCAPE
LIST OF TABLES
- TABLE 1: MARKET SNAPSHOT - CANCER PAIN MANAGEMENT
- TABLE 2: JAPAN CANCER PAIN MANAGEMENT MARKET, BY DRUG TYPE, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
- TABLE 3: JAPAN CANCER PAIN MANAGEMENT MARKET, BY DRUG TYPE, FORECAST YEARS, 2024-2032 (IN $ MILLION)
- TABLE 4: JAPAN CANCER PAIN MANAGEMENT MARKET, BY MORPHINE, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
- TABLE 5: JAPAN CANCER PAIN MANAGEMENT MARKET, BY MORPHINE, FORECAST YEARS, 2024-2032 (IN $ MILLION)
- TABLE 6: JAPAN CANCER PAIN MANAGEMENT MARKET, BY DISEASE INDICATION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
- TABLE 7: JAPAN CANCER PAIN MANAGEMENT MARKET, BY DISEASE INDICATION, FORECAST YEARS, 2024-2032 (IN $ MILLION)
- TABLE 8: LIST OF MERGERS & ACQUISITIONS
- TABLE 9: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS
- TABLE 10: LIST OF PARTNERSHIPS & AGREEMENTS
- TABLE 11: LIST OF BUSINESS EXPANSIONS & DIVESTITURES
LIST OF FIGURES
